Ganaxolone for use in treatment of status epilepticus
AssigneeMarinus Pharmaceuticals
InventorsDavid Czekai, Maciej Gasior, Lorianne Masuoka, Julia Tsai, Joseph Hulihan, Alex Aimetti
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.
Claims21
A method of treating status epilepticus (SE), comprising administering to a subject in need thereof an effective amount of ganaxolone to suppress SE, wherein the effective amount of ganaxolone is administered as an intravenous bolus plus continuous infusion to produce and maintain a ganaxolone plasma concentration of about 500 ng/ml to about 1000 ng/ml for about 8 hours to about 12 hours.
Dependencies are inferred from the claim text.